Q4 2025 Earnings Call March 3, 2026 Disclaimer Forward-looking Statements 2 Latham: A Compelling Long-term Growth Story Industry leader benefiting from increased adoption of Fiberglass Pools and Autocovers Certain statements in this presentation constitute forward-looking statements under federal securities laws. These forward-looking statements reflect our views with respect to future events and financial performance as of the date of this presentation or otherwise specified herein. Actual events and resul ...

Group 1 - The article discusses the relevance of lean manufacturing in today's corporate environment, highlighting that while many companies focus on digital transformation and AI, some leaders still advocate for traditional continuous improvement methods [1][2]. - Tom Polen, CEO of Becton, Dickinson and Company (BD), emphasizes the importance of lean manufacturing, stating that it is essential for effectively leveraging AI within the company [2][3]. - BD has significantly scaled its lean practices, increasing kaizen projects from 50 to 1,500 in one year, demonstrating a strong commitment to continuous improvement [2][3]. Group 2 - BD's recent spinoff of its $3.3 billion bioscience and diagnostic solutions units allows the company to concentrate on its $18.5 billion medical technology business, showcasing a strategic shift in focus [3]. - Despite facing pricing pressures in China and other challenges, BD's stock has risen by 19% this year, outperforming the S&P 500, which remains flat [3]. - Polen advocates for a cultural shift within the company, emphasizing the importance of celebrating continuous improvement behaviors alongside financial outcomes [3].

Core Insights - GE HealthCare Technologies debuted as a standalone public company on January 4, 2023, and its stock has increased by almost 50% since then [1] - The company is part of the breakup of General Electric, which has a long history dating back to 1892 [1] - GE HealthCare is led by CEO Peter J. Arduini, who emphasizes innovation and a focus on the medical technology and digital health sectors [1] Company Strategy - The decision to spin off GE HealthCare was driven by the need for greater focus and quicker decision-making in a rapidly evolving market [7] - The company has significantly increased its research and development budget from approximately $750 million to over $1.4 billion, effectively doubling its investment [10] - Lean manufacturing principles and a new management system have been implemented to enhance operational efficiency [11] Market Position - The medical technology industry is predominantly based in the United States, with over 70% of products manufactured domestically [17] - The company is adapting its supply chain strategy post-COVID, moving towards more localized production to enhance competitiveness [18][19] - China is viewed as a critical market, with a significant population still lacking adequate healthcare, presenting substantial growth opportunities [20] Leadership and Culture - The leadership style under CEO Arduini emphasizes authenticity and direct communication with employees, leveraging social media for engagement [21][22] - The company aims to foster a culture of servant leadership and teamwork, focusing on customer-centric values [15]

Core Viewpoint - GE Vernova is experiencing significant growth, with a doubling of its dividend and an increase in its buyback plan, indicating strong confidence in its future performance [1] Company Performance - The company reported $37 billion in revenue with an 8.5% EBITDA margin, projecting growth to $52 billion in revenue and a 20% EBITDA margin by 2028 [3] - The backlog is currently $135 billion and is expected to grow to $200 billion by 2028, reflecting strong demand for its products [5] Industry Context - The global energy demand is increasing, with a shift towards electric power, which currently constitutes 20% of the world's energy and is expected to double [4] - The company is investing in robotics and AI to enhance productivity, contributing to margin expansion [5] Revenue Streams - The power business generates $19 billion in revenue, with services currently at $12 billion, projected to grow to $22 billion by 2035, indicating a shift towards higher-margin service revenue [8] Future Outlook - The company is focused on delivering its growth framework through 2028, with discussions about long-term strategies for the 2030s anticipated soon [9] - There is a strong emphasis on developing the nuclear industry in the U.S., with recent grants and projects indicating progress in this area [12]

Summary of GE Vernova Investor Update - December 09, 2025 Company Overview - **Company**: GE Vernova (NYSE: GEV) - **Industry**: Energy and Electrification Key Themes and Insights 1. **Growth Opportunities**: The company is experiencing accelerated growth driven by several factors including AI, U.S. reindustrialization, global industrial growth, electrification of buildings, and transportation [6][22][24] 2. **Infrastructure Challenges**: The transition to a larger market will take time due to the complexities of infrastructure development, permitting, and construction [6][7] 3. **Market Position**: GE Vernova is well-positioned with the largest installed base, providing over 50% of the electrons consumed in the U.S. and a third globally (excluding China) [7][8] 4. **Energy Market Dynamics**: The global energy market is valued at over $1.5 trillion, with only 20% currently from electric power. This proportion is expected to grow significantly [9][10] 5. **Contract Wins**: The company secured 18 gigawatts of new gas contracts in the current quarter, with expectations to end the year with approximately 80 gigawatts on contract [10][11] Financial Outlook 1. **Revenue Projections**: GE Vernova projects at least $52 billion in revenue by 2028, with an adjusted EBITDA margin of 20% [17][38] 2. **Free Cash Flow**: Cumulative free cash flow is expected to reach $22 billion from 2025 to 2028, after investing $10 billion in capital expenditures and R&D [17][34] 3. **Capital Allocation**: The company plans to return $3.6 billion to shareholders in 2025, primarily through stock buybacks, and has increased its buyback program from $6 billion to $10 billion [20][35] Segment Performance 1. **Gas Power**: The gas power segment is expected to achieve a run rate of 20 gigawatts annualized by mid-2026, with significant productivity improvements anticipated [26][27] 2. **Electrification**: This segment is projected to grow mid-20% in 2025, with a backlog that has increased fourfold since the end of 2022 [18][30] 3. **Wind Energy**: While wind revenue is expected to decline, the company anticipates improved EBITDA losses in 2026 due to productivity gains [27][33] Strategic Initiatives 1. **Acquisitions**: The planned acquisition of Prolec GE is expected to enhance the company's capabilities in low voltage and grid reliability solutions [8][19] 2. **Nuclear Investments**: GE Vernova is actively working with the U.S. government to re-establish a nuclear industry, with a memorandum of understanding for up to $100 billion in small modular reactor (SMR) industrialization [14][48] 3. **Innovation and R&D**: The company is investing in new technologies such as carbon capture and solid-state transformers, with expectations for commercialization in the coming years [50][51] Cultural and Operational Focus 1. **Workforce Development**: GE Vernova emphasizes the importance of attracting young talent and fostering a strong company culture to drive future growth [52][53] 2. **Lean Operations**: The company is implementing lean practices across its manufacturing processes to enhance productivity and reduce costs [32][31] Conclusion - GE Vernova is positioned for significant growth in the energy sector, with a strong focus on electrification, gas power, and innovative technologies. The company aims to leverage its market position and operational efficiencies to achieve its ambitious financial targets by 2028 and beyond [58][59]

Core Insights - Exco Technologies Limited reported its fourth quarter and full year results for the period ending September 30, 2025, highlighting a quarterly dividend of $0.105 per common share to be paid on December 31, 2025 [1][2] Financial Performance - Consolidated sales for Q4 2025 were $150.7 million, a decrease of 3% from $155.4 million in Q4 2024, with foreign exchange movements contributing an increase of $4.1 million [4] - Net income for Q4 2025 was $8.2 million ($0.22 per share), compared to $7.7 million ($0.20 per share) in the same quarter last year [10] - EBITDA for Q4 2025 was $18.0 million, representing 12% of sales, down from $20.6 million (13%) in Q4 2024 [13] - Free cash flow for Q4 was $13.8 million, with annual free cash flow totaling $40.7 million [8] Segment Performance - The Automotive Solutions segment reported Q4 sales of $77.9 million, down 2% year-over-year, primarily due to program-launch delays and an unfavorable vehicle mix [5] - The Casting and Extrusion segment had Q4 sales of $72.7 million, a decrease of 5%, although extrusion tooling sales increased due to diverse end markets [7] - Pretax profit in the Automotive Solutions segment fell by 35% to $5.1 million, while the Casting and Extrusion segment's pretax profit decreased by 29% to $4.5 million [11][12] Strategic Outlook - The company is optimistic about future growth driven by new program launches and reshoring initiatives, which are expected to enhance sales and margins [6][17] - Exco anticipates that products compliant with USMCA rules will remain exempt from tariffs, positioning the company favorably amid ongoing trade policy developments [16] - Management remains focused on operational efficiency and market share gains through strategic pricing initiatives and lean manufacturing principles [12][14] Market Conditions - The automotive industry faces challenges such as tariff uncertainties and consumer affordability pressures, but potential interest rate reductions and an aging vehicle fleet may support production levels [5][15] - Demand for tooling, particularly in the USMCA region, is expected to increase as OEMs seek to avoid tariffs and reduce supply chain risks [9]

Heritage Global Inc. Conference Summary Company Overview - Heritage Global Inc. trades on NASDAQ with a market cap of approximately $80 million and has a history of profitability, consistently making $1 million to $2 million per quarter [1][2] Core Business Segments - The company operates in two divisions: industrial and financial [2] - The industrial division has evolved from traditional auctioneering to an e-commerce platform, serving large multinational clients such as Pfizer, Boeing, and Halliburton [3][4] Financial Performance - The company has maintained profitability, with quarterly earnings fluctuating between $1 million and $2 million, influenced by mergers and acquisitions (M&A) and larger auctions [4][5] - Current economic conditions have led to a slowdown in asset trading, with many companies in a "wait-and-see" mode regarding surplus asset sales [5][6] Market Dynamics - There is a significant buildup of inventories as companies transition to lean manufacturing and AI-driven processes, which will eventually necessitate the sale of older equipment [6][19] - The financial division, NLEX, has seen growth due to increased credit card debt and non-performing loans, with expectations for substantial growth in the coming years [14][16] Strategic Focus - The company aims to transition from making $1 million to $2 million per quarter to achieving $3 million to $5 million through strategic M&A [7][8] - Heritage Global has been preparing for M&A opportunities without incurring debt, currently holding a $10 million credit line [9][20] Competitive Landscape - The industrial auction market is competitive, with several large players, but Heritage Global believes it can outperform them in transactions due to its niche focus [24][25] - The company is also exploring expansion into Europe and diversifying into commercial real estate non-performing loans [25][26] Regulatory Environment - Changes in government policies, particularly regarding student loans and regional banks, may create new opportunities for Heritage Global [20][21] Future Outlook - The company is optimistic about future growth, particularly in the financial sector, as the market for non-performing loans is expected to expand significantly [14][21] - The management is committed to executing a growth strategy and has a young, dedicated team to support this vision [19] Key Takeaways - Heritage Global is positioned for growth through strategic M&A and a focus on evolving market conditions in both industrial and financial sectors [19][28] - The company has a solid financial foundation with zero debt and a plan for capital allocation, including stock repurchase programs [20][22]

Core Concept - The 5S system is a management tool that enhances productivity, efficiency, and workplace organization, originating from Japan and integral to Lean Manufacturing [1][4][5] History of 5S - The 5S system was developed in the 1950s by Toyota Motor Corporation and is closely associated with Kaizen and Total Quality Management (TQM) [1][4] - It has been widely adopted across various industries, including automotive, pharmaceutical, food, and service sectors [1] Definition and Principles of 5S - The five principles of 5S are: 1. **Seiri (Sort)**: Distinguishing necessary items from unnecessary ones to enhance workspace efficiency [1] 2. **Seiton (Set in Order)**: Organizing items logically for quick access, ensuring everything has a designated place [1] 3. **Seiso (Shine)**: Maintaining cleanliness in the workplace to identify potential issues and extend equipment life [1] 4. **Seiketsu (Standardize)**: Establishing uniform procedures and guidelines to sustain the previous steps [1] 5. **Shitsuke (Sustain)**: Integrating 5S into daily habits and organizational culture to promote self-discipline [1] Main Objectives of 5S - The primary goals of implementing 5S include: - Increasing productivity and efficiency [2] - Reducing time spent searching for tools or materials [2] - Improving product and service quality [2] - Enhancing workplace safety and minimizing accidents [2] - Creating an organized and motivating work environment [2] - Minimizing waste and unnecessary costs [2] Benefits of Implementing 5S - Economic benefits include the elimination of excess inventory and reduction of waste and repair costs [2] - Safety improvements arise from maintaining a clean and obstacle-free workspace [2] - Human factors are positively impacted, boosting employee motivation and engagement [2] - Quality enhancements lead to reduced errors and improved final product quality [2] - Organizational benefits lay the groundwork for a culture of discipline and continuous improvement [2] Steps to Implement 5S - Key steps for successful implementation of 5S include: 1. Training employees and raising awareness [3] 2. Assessing the current situation and documenting it [3] 3. Starting with a pilot project in one area [3] 4. Implementing the five principles step by step [3] 5. Standardizing procedures and creating guidelines [3] 6. Auditing, monitoring, and continuously improving [3] Challenges in 5S Implementation - Common challenges faced during implementation include: - Employee resistance to change [4] - Lack of support from top management [4] - Inconsistent execution, particularly in sustaining 5S [4] - Insufficient training and awareness [4] - Superficial application done only for audits [4] Case Studies of Successful 5S Implementation - Notable examples of successful 5S implementation include: - Toyota, which significantly improved productivity [4] - Honda, achieving a 30% increase in efficiency post-implementation [4] - Pharmaceutical companies that reduced human errors and improved safety [4] - Service and administrative sectors that increased service speed and customer satisfaction [4] Conclusion - 5S is not merely a method for workplace organization but a culture that fosters order, productivity, safety, and continuous improvement, serving as a foundation for other management systems [4]

Financial Data and Key Metrics Changes - The company reported a strong Q2 performance with significant revenue beats, indicating stabilization in end markets [5][9] - Operating margins improved due to better tariff conditions and effective expense management, with a 200 basis point increase in operating margin outlook for the year [7][42] - Cash flow was strong, with a focus on free cash flow generation [8] Business Line Data and Key Metrics Changes - The Process Chrome segment showed strong performance, with over 50% growth in Q2, contributing positively to the overall revenue [10][14] - Consumables experienced consistent growth year-over-year, while instrument sales faced challenges, particularly in the biopharma sector [6][17] - The Droplet Digital PCR (ddPCR) portfolio expansion is expected to drive mid-single-digit growth rates in the near term, with long-term goals of reaching high single-digit growth [29][30] Market Data and Key Metrics Changes - The U.S. academic and government (A and G) market is stabilizing, with expectations of a decline of 0% to -10% rather than the previously anticipated -20% [22] - European markets, particularly France and Germany, are under pressure due to shifts in funding from healthcare to defense [23] - The Chinese market remains challenging, with reimbursement rate changes impacting the diagnostics business, but growth outside of China was reported at 3.7% [50][49] Company Strategy and Development Direction - The company aims to invest in growth opportunities and is focusing on strategic acquisitions that can provide near-term accretion, such as the recent Stila acquisition [90] - There is an emphasis on improving working capital efficiency and leveraging procurement to enhance margins [68][70] - The company is also looking to expand its presence in diagnostics, particularly in oncology applications [32] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the stability of the business, noting improved visibility compared to previous years [13][14] - The resolution of the NIH budget is expected to gradually rebuild trust among researchers, which may positively impact instrument sales in the future [24] - The company is preparing for a potential recovery in the diagnostics market, particularly as it relates to the adoption of new technologies [32] Other Important Information - The company closed the Stila acquisition at the end of Q2, with expectations of revenue contribution in the second half of the year being lower than initially projected [34][38] - The impact of tariffs has been mitigated, with a reduction in the anticipated headwind from 130 basis points to 30-40 basis points [53] Q&A Session Summary Question: How is the visibility for Process Chrome compared to previous periods? - Management indicated that visibility has improved significantly due to better partnerships with customers, leading to a more stable business outlook [13][14] Question: What is the outlook for the U.S. A and G market? - The company expects the U.S. A and G market to remain stable, with no significant budget flush anticipated [25][26] Question: What are the growth expectations for ddPCR? - The company anticipates mid-single-digit growth in the near term, with long-term goals of reaching high single-digit growth rates [30][31] Question: How is the company addressing working capital efficiency? - Management acknowledged the need for improvement in working capital efficiency and is implementing initiatives to enhance inventory turnover and procurement leverage [68][70] Question: What is the capital allocation strategy moving forward? - The company plans to invest in growth opportunities, pursue strategic acquisitions, and continue share repurchases opportunistically [90][91]

Financial Data and Key Metrics Changes - The company reported a strong Q2 performance with significant revenue beats, indicating stabilization in end markets, particularly in process chromatography, which was driven by customer demand [4][6] - Operating margin improved due to stabilization of tariff situations and effective expense management, with cash flow also being strong during the quarter [5][6] Business Line Data and Key Metrics Changes - Process chromatography showed strong performance, contributing significantly to revenue growth, with visibility improving compared to previous years [7][8] - The life science business is experiencing challenges in the instrument segment, while consumables are seeing consistent activity [11][14] Market Data and Key Metrics Changes - The U.S. academic and government (A&G) market is expected to remain stable, with a potential decline of 0% to -10% year-over-year, while Europe faces pressures due to geopolitical issues [14][15] - The Chinese market is experiencing challenges, but Japan and Korea have shown improvement [15] Company Strategy and Development Direction - The company is focused on expanding its portfolio, particularly in the ddPCR segment, with expectations of mid-single-digit growth rates in the near term and aspirations for high single-digit growth in the long term [21][24] - The acquisition of Stillia is expected to contribute to revenue growth, with a focus on integrating teams and products effectively [25][30] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the operating environment, noting that while there are challenges, there are also opportunities for growth, particularly in diagnostics and life sciences [24][37] - The company is monitoring the impact of tariffs and reimbursement changes, particularly in China, and is focused on improving working capital efficiency [39][54] Other Important Information - The company is implementing lean manufacturing concepts to improve productivity and efficiency within its supply chain [46][48] - There is a focus on capital allocation towards business investments and strategic acquisitions, with share repurchases being considered opportunistically [72][73] Q&A Session Summary Question: What is the outlook for the U.S. A&G market? - Management indicated that the U.S. A&G market is expected to remain stable, with no significant budget flush anticipated [14][17] Question: How is the ddPCR portfolio expected to grow? - The company expects the ddPCR growth rate to improve from low singles to mid-singles, driven by an expanded portfolio [21][24] Question: What is the impact of tariffs on margins? - Initially, a 130 basis point headwind was expected, but this has been mitigated to about 30 to 40 basis points for the remainder of the year [40][41] Question: What are the plans for capital allocation? - The company plans to invest back into the business, focusing on strategic acquisitions and opportunistic share repurchases [72][73] Question: What is the timeline for the next investor day? - The company aims to hold an investor day in the spring, providing a three-year model from 2026 to 2028 [74]